Immunocore announces R&D leadership evolution
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: GlobeNewswire
Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice President roles (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 30 January 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that Dr. David Berman, Executive Vice President, Research and Development, will leave the Company effective 27 February 2026. Dr. Berman has accepted a Development Head role at a large commercial-stage biotech company. Immunocore does not intend to seek a direct replacement for Dr. Berman and will instead streamline its R&D structure and leverage the existing experienced leadership team. The Compan
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of DirectorsBusiness Wire
- Immunocore (NASDAQ:IMCR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Levicept Announces the Appointment of James Sandy as Chief Development Officer [Yahoo! Finance]Yahoo! Finance
- Levicept Announces the Appointment of James Sandy as Chief Development OfficerGlobeNewswire
- Assessing Immunocore Holdings (IMCR) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
IMCR
Earnings
- 11/6/25 - Beat
IMCR
Sec Filings
- 1/30/26 - Form 8-K
- 1/9/26 - Form 8-K
- 12/8/25 - Form 4
- IMCR's page on the SEC website